Abstract:The saponin Astragaloside IV (ASI) reportedly enhances endothelial NOS (eNOS) activity by increasing the scavenging of reactive oxygen species (ROS) and NO production. We hypothesized that oxidative stress may decrease eNOS phosphorylation and result in diastolic dysfunction in DOCA-salt mice, which could be reversed by ASI treatment.We used the deoxycorticosterone acetate (DOCA)-salt mouse model. The mice were divided into four groups; SHAM and DOCA control mice received sterile water, SHAM+ASI and DOCA+ASI received ASI treatment via an intraperitoneal injection of 0.02 mg/kg/day for 7 days. Diastolic function was assessed by echocardiography and IonOptix. The levels of eNOS monomers, dimers and phosphorylation were determined with a Western blot analysis. High performance liquid chromatography was used to measure the cardiac superoxide anions and biopterins.DOCA mice exhibited diastolic dysfunction that was reversed after ASI treatment (E'/A': SHAM vs. DOCA 1.27 ± 0.13 vs. 0.62 ± 0.07, p < 0.001; DOCA vs. DOCA+ASI 0.62 ± 0.07 vs. 1.27 ± 0.29, p = 0.002. E/E': SHAM vs. DOCA 23.90 ± 4.58 vs. 38.83 ± 4.37, p = 0.001; DOCA vs. DOCA+ASI 23.90 ± 4.58 vs. 25.28 ± 3.40, p = 0.001). Isolated myocytes from the DOCA-salt mice demonstrated impaired relaxation, diastolic sarcomere length and re-lengthening, which were restored by ASI treatment. The DOCA mice showed increased superoxide production and reduced NO production, which were alleviated by ASI. Our results showed that the levels of eNOS dimers, eNOS-S1177 and eNOS-T495 were significantly decreased in the DOCA-salt mice compared with the SHAM mice. The level of eNOS-S1177 was increased in the DOCA+ASI mice compared with the untreated DOCA-salt mice (p = 0.026); however, ASI did not affect the phosphorylation of eNOS-T495. MyBP-C S-glutathionylation increased after ASI treatment in the DOCA+ASI mice compared with the DOCA-salt hypertensive mice (p = 0.046).The decrease in eNOS dimerization and phosphorylation correlated with diastolic dysfunction, which was reversed by ASI in DOCA mice. The anti-oxidative effects of ASI on MyBP-C glutathionylation and eNOS phosphorylation preserved cardiac relaxation.(Figure is included in full-text article.).

Astragaloside IV Promotes the Enos/no/cgmp Pathway and Improves Left Ventricular Diastolic Function in Rats with Metabolic Syndrome.

Astragaloside IV improves metabolic syndrome and endothelium dysfunction in fructose-fed rats

Effects of Astragaloside IV on Pathogenesis of Metabolic Syndrome in Vitro

Effect of Astragaloside IV on Hepatic Glucose‐regulating Enzymes in Diabetic Mice Induced by a High‐fat Diet and Streptozotocin

Astragaloside Iv Improves Left Ventricular Diastolic Dysfunction In Hypertensive Mice By Increasing The Phosphorylation Of Endothelial Nitric Oxide Synthase

Astragaloside IV inhibits ventricular remodeling and improves fatty acid utilization in rats with chronic heart failure

Astragaloside IV alleviates heart failure via activating PPARα to switch glycolysis to fatty acid β-oxidation

Astragaloside IV Reduces OxLDL-Induced BNP Overexpression by Regulating HDAC

Astragaloside IV inhibits proliferation and promotes apoptosis in rat vascular smooth muscle cells under high glucose concentration in vitro.

Molecular Mechanism of Astragaloside IV in Improving Endothelial Dysfunction of Cardiovascular Diseases Mediated by Oxidative Stress

Effect of Astragaloside IV on improving cardiac function in rats with heart failure: a preclinical systematic review and meta-analysis

Astragaloside IV for Heart Failure: Preclinical Evidence and Possible Mechanisms, A Systematic Review and Meta-Analysis

Astragaloside IV ameliorates pressure overload-induced heart failure by enhancing angiogenesis through HSF1/VEGF pathway

Astragaloside IV Ameliorates Isoprenaline-Induced Cardiac Fibrosis in Mice via Modulating Gut Microbiota and Fecal Metabolites

The Key Role Of Astragalus Membranaceus On Improving The Cardiac Diastolic Function Of Postmenopausal Hypertension Women With Metabolic Syndrome

Astragaloside IV Protects Against Diabetic Nephropathy Via Activating Enos in Streptozotocin Diabetes-Induced Rats

Beneficial effects of astragaloside IV against angiotensin II-induced mitochondrial dysfunction in rat vascular smooth muscle cells

The Mechanism Actions of Astragaloside IV Prevents the Progression of Hypertensive Heart Disease Based on Network Pharmacology and Experimental Pharmacology

Astragaloside IV alleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway

Astragaloside IV Exerts a Myocardial Protective Effect against Cardiac Hypertrophy in Rats, Partially via Activating the Nrf2/HO-1 Signaling Pathway

Astragaloside IV alleviates myocardial damage induced by type 2 diabetes via improving energy metabolism